体外毒性試験市場：タイプ別（吸収、有害物質、投与量）、技術別（細胞培養技術、ハイスループット技術、トキシコゲノミクス）、エンドユーザー別（化粧品・家庭用品、医薬品産業、食品産業、化学品産業）。世界の市場機会分析および産業予測、2020-2030年

In Vitro Toxicity Testing Market By Type (Absorption, Toxic Substances, Dose), By Techniology (Cell Culture Technologies, High Throughput Technologies, Toxicogenomics), By End User (Cosmetics and Households Products, Pharmaceuticals Industry, Food Industry, Chemicals Industry): Global Opportunity Analysis and Industry Forecast, 2020-2030

世界の試験管内毒性試験市場は、2020年に185億6520万ドル、2030年には591億4760万ドルに達し、2020年から2030年までのCAGRは12.0％で成長すると予測されています。試験管内とは、試験管や培養皿の中、あるいは... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Allied Market Research アライドマーケットリサーチ	2022年5月31日	US$5,939 シングルユーザーライセンスライセンス・価格情報・注文方法はこちら	231	英語

サマリー

世界の試験管内毒性試験市場は、2020年に185億6520万ドル、2030年には591億4760万ドルに達し、2020年から2030年までのCAGRは12.0％で成長すると予測されています。
試験管内とは、試験管や培養皿の中、あるいは生体の外で実験を行うことです。試験管内毒性試験（IVTT）は、有害な化学物質が培養細菌に及ぼす影響を調べるものです。医薬品、化粧品、食品添加物などの新製品開発において、有害な化学物質を特定し、その毒性の早期発見に役立てられています。主に医薬品開発における安全性評価や、化学物質の力価に応じたランク付けに利用されています。また、薬物の吸収・分布・代謝・排泄（ADME）、用量反応、閾値反応もこの方法で決定される。
試験管内毒性試験の世界市場の成長は、この方法を試験に使用することに対する規制当局の受け入れが増加したことに牽引されています。さらに、動物実験の禁止や環境問題に対する意識の高まりが市場の成長を後押ししています。しかし、in vitro毒性試験キットの採用率の低下や、自己免疫・免疫賦活を判定するin vitroモデルの無力化などの要因が、市場の成長を抑制しています。逆に、3D細胞培養の新しいアプローチへの注目の高まりや、遺伝学および遺伝子スクリーニングアプローチの進歩は、市場拡大のための潜在的な機会を提供すると期待されます。
試験管内毒性試験市場は、タイプ、技術、エンドユーザー、地域に区分されます。タイプ別に見ると、市場は吸収、毒性物質、投与量に分類されます。現在、吸収分野が世界の体外毒性試験市場を支配しています。
エンドユーザーに基づいて、市場は医薬品、化粧品および家庭用品、化学工業、食品工業に分類されます。エンドユーザーの中では、化粧品・家庭用品分野が圧倒的に多く、次いで製薬業界となっています。In vitro毒性試験市場は、技術別に、細胞培養技術、ハイスループットテクノロジー、トキシコゲノミクスに分類されます。細胞培養技術セグメントは、2020年に最も高い収益を生み出しました。
地域別では、in vitro毒性試験市場は、北米、ヨーロッパ、アジア太平洋、LAMEAで分析されます。北米が最も高い収益成長で、欧州がそれに続く。LAMEAは予測期間中にCAGR16.7%となり、アジア太平洋よりも速い成長を遂げると予測される。LAMEAセグメントは、in vitro毒性試験市場を支配すると予測されます。
市場で事業を展開する主なプレイヤーには、Acacia Pharma Group Plc.、AstraZeneca Plc、GlaxoSmithKline Plc、Helsinn Holdings S.A.、Haron Therapeutics Inc.、General Electric Company、EISAI Pharmaceutical Pvt Ltd.、Catalent、Laboratory Corporation of America Holdings、Thermo Fisher Scientific、Inc.が含まれます。
グラクソ・スミスクライン・ピーエルシー（GSK）、ゼネラル・エレクトリック・カンパニー、アストラゼネカ・ピーエルシーなどの大手企業は、市場での競争を維持するために、製品ポートフォリオを改善する買収戦略を採用しています。例えば、AstraZenecaは2021年7月にAlexion pharmaceuticals, Inc.の買収を完了しました。この買収は、免疫学における科学的プレゼンスを高めることを目的としており、アレクシオンの革新的な補体生物学プラットフォームと強固なパイプラインを通じて、希少疾患患者のための医薬品の発見と開発を開拓し続けることが期待されます。このような事例は、市場成長のために主要なプレーヤーに有利な機会を提供することが期待されます。

ページTOPに戻る

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: IN VITRO TOXICITY TESTING MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Absorption
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Toxic Substances
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Dose
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: IN VITRO TOXICITY TESTING MARKET, BY TECHNIOLOGY
5.1 Overview
5.1.1 Market size and forecast
5.2 Cell Culture Technologies
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 High Throughput Technologies
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Toxicogenomics
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: IN VITRO TOXICITY TESTING MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Cosmetics and Households Products
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Pharmaceuticals Industry
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Food Industry
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
6.5 Chemicals Industry
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market analysis by country
CHAPTER 7: IN VITRO TOXICITY TESTING MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Techniology
7.2.4 North America Market size and forecast, by End User
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Techniology
7.2.5.1.3 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Techniology
7.2.5.2.3 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Techniology
7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Techniology
7.3.4 Europe Market size and forecast, by End User
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Techniology
7.3.5.1.3 Market size and forecast, by End User
7.3.5.2 Italy
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Techniology
7.3.5.2.3 Market size and forecast, by End User
7.3.5.3 France
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Techniology
7.3.5.3.3 Market size and forecast, by End User
7.3.5.4 Spain
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Techniology
7.3.5.4.3 Market size and forecast, by End User
7.3.5.5 Rest of Europe
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Techniology
7.3.5.5.3 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Techniology
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Techniology
7.4.5.1.3 Market size and forecast, by End User
7.4.5.2 Japan
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Techniology
7.4.5.2.3 Market size and forecast, by End User
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Techniology
7.4.5.3.3 Market size and forecast, by End User
7.4.5.4 South Korea
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Techniology
7.4.5.4.3 Market size and forecast, by End User
7.4.5.5 Rest Of Asia Pacific
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Techniology
7.4.5.5.3 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Techniology
7.5.4 LAMEA Market size and forecast, by End User
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Latin America
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Techniology
7.5.5.1.3 Market size and forecast, by End User
7.5.5.2 Middle East
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Techniology
7.5.5.2.3 Market size and forecast, by End User
7.5.5.3 Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Techniology
7.5.5.3.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 General Electric Company
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Thermo Fisher Scientific, Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Laboratory Corporation of America Holdings
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 ACACIA PHARMA GROUP PLC
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 TESARO INC.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Helsinn Holding S.A.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Heron Therapeutics Inc
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 AstraZeneca plc
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Catalent Inc
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL IN VITRO TOXICITY TESTING MARKET, BY TYPE, 2020-2030,($MILLION)
TABLE 2. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR ABSORPTION, BY REGION , 2020-2030,($MILLION)
TABLE 3. IN VITRO TOXICITY TESTING MARKET ABSORPTION BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR TOXIC SUBSTANCES, BY REGION , 2020-2030,($MILLION)
TABLE 5. IN VITRO TOXICITY TESTING MARKET TOXIC SUBSTANCES BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR DOSE, BY REGION , 2020-2030,($MILLION)
TABLE 7. IN VITRO TOXICITY TESTING MARKET DOSE BY COUNTRY, 2020-2030,($MILLION)
TABLE 8. GLOBAL IN VITRO TOXICITY TESTING MARKET, BY TECHNIOLOGY, 2020-2030,($MILLION)
TABLE 9. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR CELL CULTURE TECHNOLOGIES, BY REGION , 2020-2030,($MILLION)
TABLE 10. IN VITRO TOXICITY TESTING MARKET CELL CULTURE TECHNOLOGIES BY COUNTRY, 2020-2030,($MILLION)
TABLE 11. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR HIGH THROUGHPUT TECHNOLOGIES, BY REGION , 2020-2030,($MILLION)
TABLE 12. IN VITRO TOXICITY TESTING MARKET HIGH THROUGHPUT TECHNOLOGIES BY COUNTRY, 2020-2030,($MILLION)
TABLE 13. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR TOXICOGENOMICS, BY REGION , 2020-2030,($MILLION)
TABLE 14. IN VITRO TOXICITY TESTING MARKET TOXICOGENOMICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 15. GLOBAL IN VITRO TOXICITY TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 16. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR COSMETICS AND HOUSEHOLDS PRODUCTS, BY REGION , 2020-2030,($MILLION)
TABLE 17. IN VITRO TOXICITY TESTING MARKET COSMETICS AND HOUSEHOLDS PRODUCTS BY COUNTRY, 2020-2030,($MILLION)
TABLE 18. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR PHARMACEUTICALS INDUSTRY, BY REGION , 2020-2030,($MILLION)
TABLE 19. IN VITRO TOXICITY TESTING MARKET PHARMACEUTICALS INDUSTRY BY COUNTRY, 2020-2030,($MILLION)
TABLE 20. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR FOOD INDUSTRY, BY REGION , 2020-2030,($MILLION)
TABLE 21. IN VITRO TOXICITY TESTING MARKET FOOD INDUSTRY BY COUNTRY, 2020-2030,($MILLION)
TABLE 22. IN VITRO TOXICITY TESTING MARKET REVENUE, FOR CHEMICALS INDUSTRY, BY REGION , 2020-2030,($MILLION)
TABLE 23. IN VITRO TOXICITY TESTING MARKET CHEMICALS INDUSTRY BY COUNTRY, 2020-2030,($MILLION)
TABLE 24. IN VITRO TOXICITY TESTING MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 25. NORTH AMERICA IN VITRO TOXICITY TESTING MARKET, BY TYPE, 2020-2030,($MILLION)
TABLE 26. NORTH AMERICA IN VITRO TOXICITY TESTING MARKET, BY TECHNIOLOGY, 2020-2030,($MILLION)
TABLE 27. NORTH AMERICA IN VITRO TOXICITY TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 28. NORTH AMERICA IN VITRO TOXICITY TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 29. U.S. IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 30. U.S. IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 31. U.S. IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 32. CANADA IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 33. CANADA IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 34. CANADA IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 35. MEXICO IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 36. MEXICO IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 37. MEXICO IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 38. EUROPE IN VITRO TOXICITY TESTING MARKET, BY TYPE, 2020-2030,($MILLION)
TABLE 39. EUROPE IN VITRO TOXICITY TESTING MARKET, BY TECHNIOLOGY, 2020-2030,($MILLION)
TABLE 40. EUROPE IN VITRO TOXICITY TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 41. EUROPE IN VITRO TOXICITY TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 42. GERMANY IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 43. GERMANY IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 44. GERMANY IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 45. ITALY IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 46. ITALY IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 47. ITALY IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 48. FRANCE IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 49. FRANCE IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 50. FRANCE IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 51. SPAIN IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 52. SPAIN IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 53. SPAIN IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 54. REST OF EUROPE IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 55. REST OF EUROPE IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 56. REST OF EUROPE IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 57. ASIA-PACIFIC IN VITRO TOXICITY TESTING MARKET, BY TYPE, 2020-2030,($MILLION)
TABLE 58. ASIA-PACIFIC IN VITRO TOXICITY TESTING MARKET, BY TECHNIOLOGY, 2020-2030,($MILLION)
TABLE 59. ASIA-PACIFIC IN VITRO TOXICITY TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 60. ASIA-PACIFIC IN VITRO TOXICITY TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 61. CHINA IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 62. CHINA IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 63. CHINA IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 64. JAPAN IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 65. JAPAN IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 66. JAPAN IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 67. INDIA IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 68. INDIA IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 69. INDIA IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 70. SOUTH KOREA IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 71. SOUTH KOREA IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 72. SOUTH KOREA IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 73. REST OF ASIA PACIFIC IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 74. REST OF ASIA PACIFIC IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 75. REST OF ASIA PACIFIC IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 76. LAMEA IN VITRO TOXICITY TESTING MARKET, BY TYPE, 2020-2030,($MILLION)
TABLE 77. LAMEA IN VITRO TOXICITY TESTING MARKET, BY TECHNIOLOGY, 2020-2030,($MILLION)
TABLE 78. LAMEA IN VITRO TOXICITY TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 79. LAMEA IN VITRO TOXICITY TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 80. LATIN AMERICA IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 81. LATIN AMERICA IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 82. LATIN AMERICA IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 83. MIDDLE EAST IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 84. MIDDLE EAST IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 85. MIDDLE EAST IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 86. AFRICA IN VITRO TOXICITY TESTING MARKET BY TYPE 2020-2030,($MILLION)
TABLE 87. AFRICA IN VITRO TOXICITY TESTING MARKET BY TECHNIOLOGY 2020-2030,($MILLION)
TABLE 88. AFRICA IN VITRO TOXICITY TESTING MARKET BY END USER 2020-2030,($MILLION)
TABLE 89.GENERAL ELECTRIC COMPANY: COMPANY SNAPSHOT
TABLE 90.GENERAL ELECTRIC COMPANY: OPERATING SEGMENTS
TABLE 91.GENERAL ELECTRIC COMPANY: PRODUCT PORTFOLIO
TABLE 92.GENERAL ELECTRIC COMPANY: NET SALES,
TABLE 93.GENERAL ELECTRIC COMPANY: KEY STRATERGIES
TABLE 94.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
TABLE 95.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
TABLE 96.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
TABLE 97.THERMO FISHER SCIENTIFIC, INC.: NET SALES,
TABLE 98.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES
TABLE 99.LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
TABLE 100.LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS
TABLE 101.LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
TABLE 102.LABORATORY CORPORATION OF AMERICA HOLDINGS: NET SALES,
TABLE 103.LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES
TABLE 104.ACACIA PHARMA GROUP PLC: COMPANY SNAPSHOT
TABLE 105.ACACIA PHARMA GROUP PLC: OPERATING SEGMENTS
TABLE 106.ACACIA PHARMA GROUP PLC: PRODUCT PORTFOLIO
TABLE 107.ACACIA PHARMA GROUP PLC: NET SALES,
TABLE 108.ACACIA PHARMA GROUP PLC: KEY STRATERGIES
TABLE 109.TESARO INC.: COMPANY SNAPSHOT
TABLE 110.TESARO INC.: OPERATING SEGMENTS
TABLE 111.TESARO INC.: PRODUCT PORTFOLIO
TABLE 112.TESARO INC.: NET SALES,
TABLE 113.TESARO INC.: KEY STRATERGIES
TABLE 114.HELSINN HOLDING S.A.: COMPANY SNAPSHOT
TABLE 115.HELSINN HOLDING S.A.: OPERATING SEGMENTS
TABLE 116.HELSINN HOLDING S.A.: PRODUCT PORTFOLIO
TABLE 117.HELSINN HOLDING S.A.: NET SALES,
TABLE 118.HELSINN HOLDING S.A.: KEY STRATERGIES
TABLE 119.HERON THERAPEUTICS INC: COMPANY SNAPSHOT
TABLE 120.HERON THERAPEUTICS INC: OPERATING SEGMENTS
TABLE 121.HERON THERAPEUTICS INC: PRODUCT PORTFOLIO
TABLE 122.HERON THERAPEUTICS INC: NET SALES,
TABLE 123.HERON THERAPEUTICS INC: KEY STRATERGIES
TABLE 124.ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 125.ASTRAZENECA PLC: OPERATING SEGMENTS
TABLE 126.ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 127.ASTRAZENECA PLC: NET SALES,
TABLE 128.ASTRAZENECA PLC: KEY STRATERGIES
TABLE 129.CATALENT INC: COMPANY SNAPSHOT
TABLE 130.CATALENT INC: OPERATING SEGMENTS
TABLE 131.CATALENT INC: PRODUCT PORTFOLIO
TABLE 132.CATALENT INC: NET SALES,
TABLE 133.CATALENT INC: KEY STRATERGIES

LIST OF FIGURES
FIGURE 1.IN VITRO TOXICITY TESTING MARKET SEGMENTATION
FIGURE 2.IN VITRO TOXICITY TESTING MARKET,2020-2030
FIGURE 3.IN VITRO TOXICITY TESTING MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.IN VITRO TOXICITY TESTING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.IN VITRO TOXICITY TESTING MARKET,BY TYPE,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF ABSORPTION IN VITRO TOXICITY TESTING MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF TOXIC SUBSTANCES IN VITRO TOXICITY TESTING MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DOSE IN VITRO TOXICITY TESTING MARKET,2020-2030(%)
FIGURE 15.IN VITRO TOXICITY TESTING MARKET,BY TECHNIOLOGY,2020(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CELL CULTURE TECHNOLOGIES IN VITRO TOXICITY TESTING MARKET,2020-2030(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HIGH THROUGHPUT TECHNOLOGIES IN VITRO TOXICITY TESTING MARKET,2020-2030(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF TOXICOGENOMICS IN VITRO TOXICITY TESTING MARKET,2020-2030(%)
FIGURE 19.IN VITRO TOXICITY TESTING MARKET,BY END USER,2020(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF COSMETICS AND HOUSEHOLDS PRODUCTS IN VITRO TOXICITY TESTING MARKET,2020-2030(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICALS INDUSTRY IN VITRO TOXICITY TESTING MARKET,2020-2030(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF FOOD INDUSTRY IN VITRO TOXICITY TESTING MARKET,2020-2030(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF CHEMICALS INDUSTRY IN VITRO TOXICITY TESTING MARKET,2020-2030(%)
FIGURE 24.IN VITRO TOXICITY TESTING MARKET BY REGION,2020
FIGURE 25.U.S. IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 26.CANADA IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 27.MEXICO IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 28.GERMANY IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 29.ITALY IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 30.FRANCE IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 31.SPAIN IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 32.REST OF EUROPE IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 33.CHINA IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 34.JAPAN IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 35.INDIA IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 36.SOUTH KOREA IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 37.REST OF ASIA PACIFIC IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 38.LATIN AMERICA IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 39.MIDDLE EAST IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 40.AFRICA IN VITRO TOXICITY TESTING MARKET,2020-2030($MILLION)
FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45.COMPETITIVE DASHBOARD
FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 47.GENERAL ELECTRIC COMPANY.: NET SALES ,($MILLION)
FIGURE 48.THERMO FISHER SCIENTIFIC, INC..: NET SALES ,($MILLION)
FIGURE 49.LABORATORY CORPORATION OF AMERICA HOLDINGS.: NET SALES ,($MILLION)
FIGURE 50.ACACIA PHARMA GROUP PLC.: NET SALES ,($MILLION)
FIGURE 51.TESARO INC..: NET SALES ,($MILLION)
FIGURE 52.HELSINN HOLDING S.A..: NET SALES ,($MILLION)
FIGURE 53.HERON THERAPEUTICS INC.: NET SALES ,($MILLION)
FIGURE 54.ASTRAZENECA PLC.: NET SALES ,($MILLION)
FIGURE 55.CATALENT INC.: NET SALES ,($MILLION)

ページTOPに戻る

Table of Contents

Summary

The global in vitro toxicity testing market was valued at $18,565.2 million in 2020 and is projected to reach $59,147.6 million by 2030, growing at a CAGR of 12.0% from 2020 to 2030.
In vitro is the process of performing experiments in a test tube, culture dish, or outside a living organism. In vitro toxicity testing (IVTT) examines the effects of toxic chemical substances on cultured bacteria. It is used to identify hazardous chemical substances and helps detect the toxicity at early stages of the development of new products, such as drugs, cosmetics, and food additives. It is majorly used for safety evaluation in drug development and for ranking the chemicals according to their potency. Moreover, absorption, distribution, metabolism, and excretion (ADME), dose response, and threshold response of drugs are determined by this method.
The growth of the global in vitro toxicity testing market is driven by increase in acceptance by regulatory authorities for using this method for testing. Moreover, ban on animal testing and increase in awareness towards environmental concerns boost the market growth. However, factors such as reduction in adoption rate of in vitro toxicity testing kits and incapability of in vitro models to determine autoimmunity & immunostimulation restrain the market growth. Conversely, rise in focus towards new approaches of 3D cell culture and advancement in genetics & genetic screening approaches are expected to provide potential opportunities for market expansion.
The in vitro toxicity testing market is segmented into type, technology, end users, and region. On the basis of type, the market is categorized into absorption, toxic substances, and dose. Currently, the absorption segment dominates the global in vitro toxicity testing market.
On the basis of end user, the market is categorized into pharmaceuticals, cosmetics & household products, chemicals industry, and food industry. The cosmetics and households products segment is dominant among end users, followed by the pharmaceutical industry. On the basis of technology, the in vitro toxicity testing market is segmented in to cell culture technologies, high throughput technologies, and toxicogenomics. The cell culture technologies segment generated the highest revenue in 2020.
On the basis of region, the in vitro toxicity testing market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is the highest revenue growth, followed by Europe. LAMEA is predicted to grow faster than Asia-Pacific with a CAGR of 16.7% during the forecast period. The LAMEA segment is expected to dominate the in vitro toxicity testing market.
The key players operating in the market include, Acacia Pharma Group Plc., AstraZeneca Plc, GlaxoSmithKline Plc, Helsinn Holdings S.A., Heron Therapeutics Inc., Inc., General Electric Company, EISAI Pharmaceutical Pvt Ltd., Catalent, Inc., Laboratory Corporation of America Holdings., and Thermo Fisher Scientific, Inc.
Major players, such as GlaxoSmithKline Plc (GSK), General Electric Company, AstraZeneca Plc, and others are adopting the acquisition strategy to improve their product portfolio to maintain competition in the market. For instance, AstraZeneca completed the acquisition of Alexion pharmaceuticals, Inc. in July 2021. This acquisition aims to enhance scientific presence in immunology and through Alexion's innovative complement-biology platform and robust pipeline, and is expected to continue to pioneer the discovery and development of medicines for patients with rare diseases. Such instances are expected to provide lucrative opportunities for the major players for the growth of the market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

Allied Market Research 社の最新刊レポート

本レポートと同じKEY WORD（cosmetics）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

アライドマーケットリサーチ（Allied Market Research）は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（その他）の最新刊レポート

Allied Market Research 社の最新刊レポート

本レポートと同じKEY WORD（cosmetics）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?